Table 6 Diagnostic utility of TNF-beta concentration evaluation in combination with bFGF, IL-9, IL-18, or TNF-alpha for differentiating papillary thyroid cancer from nodular thyroid goiter.

From: Preliminary results suggest the potential of evaluating combined bFGF and TNF-β concentrations for differentiating papillary thyroid cancer from benign nodular goiter

 

Cut-off

Youden index

AUC ± SE

Se [%] (CI)

Sp [%] (CI)

PPV [%]

NPV [%]

ACC [%]

p-value

TNF-beta + bFGF

0.69

0.40

0.709 ± 0.067

44 (0.266–0.609)

96 (0.888–1.035)

93

58

67

0.0018

TNF-beta + IL-9

0.67

0.42

0.714 ± 0.067

50 (0.327–0.673)

92 (0.821–1.026)

89

60

69

0.0015

TNF-beta + IL-18

0.21

0.47

0.745 ± 0.067

78 (0.638–0.924)

69 (0.515–0.870)

74

72

74

0.0002

TNF-beta + TNF-alpha

0.53

0.46

0.743 ± 0.064

66 (0.492–0.821)

81 (0.656–0.959)

72

81

66

0.0002

  1. Confidence intervals (CIs) for sensitivity and specificity were calculated at a 95% confidence level (1-α = 0.95) using the C.I. Calculator: Diagnostic Statistics software (https://www2.ccrb.cuhk.edu.hk/stat/confidence%20interval/Diagnostic%20Statistic.htm).
  2. bFGF basic fibroblast growth factor, CI confidence interval, IL-9 interleukin-9, IL-18 interleukin-18, TNF-alpha tumor necrosis factor alpha, TNF-beta tumor necrosis factor beta, ACC diagnostic accuracy, AUC area under the ROC curve; Cut-off (based on the highest Youden index), NPV negative predictive value, PPV positive predictive value, Se diagnostic sensitivity, SE standard error, Sp diagnostic specificity.
Back to article page